Ekso Bionics (NASDAQ:EKSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Friday morning. The brokerage issued a hold rating on the stock.

Other equities analysts also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Ekso Bionics in a report on Tuesday, July 30th. Lake Street Capital assumed coverage on shares of Ekso Bionics in a research report on Monday, June 24th. They set a “buy” rating and a $2.50 price target on the stock.

Ekso Bionics Price Performance

Shares of EKSO opened at $1.03 on Friday. The business’s fifty day moving average is $1.09 and its 200 day moving average is $1.16. Ekso Bionics has a 12-month low of $0.75 and a 12-month high of $3.13. The company has a quick ratio of 1.77, a current ratio of 2.42 and a debt-to-equity ratio of 0.36. The stock has a market cap of $18.72 million, a P/E ratio of -1.06 and a beta of 1.45.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings data on Monday, July 29th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The company had revenue of $4.95 million during the quarter, compared to analysts’ expectations of $5.34 million. Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. During the same period last year, the company earned ($0.31) earnings per share. Sell-side analysts anticipate that Ekso Bionics will post -0.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC increased its stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the first quarter, according to its most recent filing with the SEC. The fund owned 596,050 shares of the company’s stock after buying an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.